Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: A randomized trial

Nephrology Dialysis Transplantation

Volumn 30, Issue 4, 2015, Pages 645-652

  Pisani, Antonio ^a   Riccio, Eleonora ^a   Sabbatini, Massimo ^a   Andreucci, Michele ^b   Del Rio, Antonio ^a   Visciano, Bianca ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

anaemia; erythropoiesis; inflammation; iron deficiency

Indexed keywords

FERRITIN; FERROUS GLUCONATE; HEMOGLOBIN; TRANSFERRIN; GLUCONIC ACID; IRON DERIVATIVE; LIPOSOME;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; INFUSION RELATED REACTION; IRON DEFICIENCY ANEMIA; LIPOSOMAL DELIVERY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ANEMIA, IRON-DEFICIENCY; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANEMIA, IRON-DEFICIENCY; FEMALE; GLUCONATES; HUMANS; IRON COMPOUNDS; LIPOSOMES; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

EID: 84926622743     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu357     Document Type: Article

References (41)

1. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191
2. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the third National Health and Nutrition examination survey. J Am Soc Nephrol 2002; 13: 504-510
3. Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134
4. Locatelli F, Aljama P, Bàràny P et al. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(Suppl 2): ii1-47
5. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 2010; 55: 726-741
6. Tsagalis G. Renal anemia: a nephrologist's view. Hyppokratia 2011; 15 (Suppl 1): 39-43
7. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: 41-46
8. Sunder-Plassmann G, Horl WH. Importance of iron supply for the erythropoietin therapy. Nephrol Dial Transplant 1995; 10: 2070-2076
9. Dreuke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New Engl J Med 2006; 335: 2071-2084
10. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
11. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbopoetin alfa in type 2 diabetes and chronic kidney disease. New Engl J Med 2009; 361: 2019-2032
12. Kidney Disease Improving Global Outcomes (KDIGO). Clinical practice guideline for anemia in chronic kidney disease. Kid Int Supp 2012; 2: 292-298
13. Macdougall IC, Bock A, Carrera F et al. The FIND-CKD study- A randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. Nephrol Dial Transplant 2014; 29: 843-850
14. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl 1999; 69: S61-S66
15. Van Wyck DB, Roppolo M, Martinez CO et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005; 68: 2846-2856
16. Charytan C, Quinbi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 2005; 100: c55-c62
17. Agarwal R, Rizkala AR, Bastani B et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006; 26: 445-454
18. VanWyck DB, Cavallo G, Spinowitz BS et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 2000; 36: 88-97
19. Walters BA, Van Wyck DB. Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients. Nephrol Dial Transplant 2005; 20: 1438-1442
20. Agarwal R, Vasavada N, Sachs NG et al. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279-2289
21. Zager RA, Johnson AC, Hanson SY. Parenteral iron therapy exacerbates experimental sepsis. Kidney Int 2004; 65: 2108-2112
22. Brewster UC, Perazella MA. Intravenous iron and the risk of infection in end-stage renal disease patients. Semin Dial 2004; 17: 57-60
23. Zager RA, Johnson AC, Hanson SY et al. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90-103
24. KDOQI; National Kidney Foundation. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006; 47: S16-S85
25. Wysowski DK, Swartz L, Borders-Hemiphill BV et al. Use of parenteral iron products and serious anaphylactic-type reaction. Am J Hematol 2010; 85: 650-654
26. Folkert VW, Michael B, Agarwal R et al. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (ge;250 mg) administration. Am J Kidney Dis 2003; 41: 651-657
27. Nissenson AR, Charytan C. Controversies in iron management. Kidney Int 2003; 64: S64-S71
28. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anemia. Drugs 2009; 69: 739-756
29. Quinbi WY, Martinez C, Smith M et al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011; 26: 1599-1607
30. Spinowitz BS, Kausz AT, Baptista J et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008; 19: 1599-1605
31. Mircescu G, Gârneata L, Capusa C et al. Intravenous iron supplementation for the treatment of anemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant 2006; 21: 120-124
32. Rosen-Zvi B, Gafter-Gvili A, Paul M et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008; 52: 897-906
33. Van Wyck DB, Martens MG, Seid MH et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obset Gynecol 2007; 110: 267-278
34. Kozubek A, Gubernator J, Przeworska E et al. Liposomal drug delivery, a novel approach: PLARosomes. Acta Biochim Pol 2000; 47: 639-649
35. Nyvad O, Danielsen H, Madsen S. Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients [letter]. Lancet 1994; 344: 1305-1306
36. Bárány P. Inflammation, serum C-reactive protein, and erythropoietin resistance. Nephrol Dial Transplant 2001; 16: 224-227
37. Gunnell J, Yeun JY, Depner TA et al. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33: 63-72
38. Del Vecchio L, Pozzoni P, Andrulli S et al. Inflammation and resistance to treatment with recombinant human erythropoietin. J Ren Nutr 2005; 15: 137-141
39. Rathaus M. C-reactive protein in the assessment of iron status in patients on hemodialysis. G Ital Nefrol 2009; 26: 338-346
40. Shouten BJ, Hunt PJ, Livesey JH et al. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 2009; 94: 2332-2337
41. Agarwal R, Leehey DJ, Olsen SM et al. Proteinuria induced by parenteral iron in chronic kidney disease- A comparative randomized controlled trial. Clin J Am Nephrol 2011; 6: 114-121